Heritas-backed Tessa Therapeutics has raised US$126 million in a Series A funding round led by US healthcare investor Polaris Partners, alongside existing investors Temasek, EDBI, Heliconia Capital and Heritas Capital.

“Heritas Capital is pleased to join Polaris Partners, Temasek, EDBI and Heliconia Capital in backing Tessa Therapeutics to advance its ongoing development of autologous and allogenic cell therapy treatments for haematological malignancies and solid tumours. Our follow-on investment into Tessa Therapeutics reflects Heritas’ commitment towards developing novel impactful solutions to address underserved healthcare needs globally,” said Dr Koh Fong Ming, Head of Life Sciences at Heritas Capital.

Read more on Tessa Therapeutics’ plans to push its assets through clinical trials here.